May 24, 2018
Lilly to seek replacement for oncology president
Eli Lilly said Thursday its senior vice president and president of Lilly Oncology, and the member of the company’s executive…
Pharmaceuticals, Biotechnology and Life Sciences
Tag: oncology
May 10, 2018
Lilly buys ARMO for $1.6 billion
Eli Lilly will buy ARMO BioSciences for $50 per share, or approximately $1.6 billion, the companies said Thursday.
February 27, 2018
Basilea gets closer to profitability with increased revenue driven by Cresemba and Zevtera sales. Aims US market with its oncology program
Basilea Pharmaceutica’s revenue in 2017 increased to CHF 101.5 million fromCHF 66.0 million in 2016, which represents an increase of…
February 12, 2018
Actinium seeks chance to maximize value for partners and collaborators, applies Acute Myeloid Leukemia treatment for investigation
Actinium Pharmaceuticals has applied an Investigational New Drug for Actimab-A combined with CLAG-M, for Acute Myeloid Leukemia, to the USFDA.
January 22, 2018
Novartis buys French radiopharmaceutical company AAA for $3.9 billion
Novartis Group France has completed a tender to buy Advanced Accelerator Applications S.A. for $3,9 billion, or $41.00 per ordinary…
December 12, 2017
Lilly strengthens its oncology department with a new name
Eli Lilly said on Monday that Kimberly Blackwell, M.D., one of the USA’s leading breast cancer researchers, will join Lilly Oncology as…
October 30, 2017
Novartis expands its oncology arm with AAA
Novartis said on Monday that it wants to buy Advanced Accelerator Applications (AAA), a radiopharmaceutical company that owns and sells…
September 20, 2017
EC approves Novartis’s cancer drug for 2 indications
The European Commission has approved Novartis’s Rydapt for two indications in rare cancers, in combination with standard daunorubicin and cytarabine…
September 11, 2017
Targovax with three oncology posters at ESMO in Spain
Targovax ASA, a clinical stage company focused on immuno-oncology therapies against solid tumors, on Monday revealed that three posters were…
July 27, 2017
Merck, AstraZeneca in a $8.5 billion oncology deal
AstraZeneca and Merck on Thursday said that they have made a deal to co-develop and co-commercialise AstraZeneca’s oncology product Lynparza (olaparib) for multiple cancer types. Lynparza is an oral poly ADP ribose polymerase (PARP) inhibitor currently approved for BRCA-mutated ovarian cancer in multiple lines of treatment.